IAVI R001
Status:Completed
Phase:I
Principal Investigator(s):John Treanor, MD
Objective:This is a dose escalation study to test the safety and immunogenicity of an oral HIV-1 vaccine.
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
Description1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
Mode of Delivery
ARMs
Description1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
Mode of Delivery
ARMs
Description1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
Mode of Delivery
ARMs
Description1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
Mode of Delivery
ARMs
Official Code:
NCT02366013
Trial Sponsors:
IAVI
Start Date
End Date
January 22, 2015
June 22, 2016
Enrollment:24
Age range:
18 Years ↔
40 Years
Population:Cisgender Men